AEON logo

AEON Biopharma, Inc. Stock Price

NYSEAM:AEON Community·US$24.0m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

AEON Share Price Performance

US$0.93
0.43 (87.25%)
US$0.93
0.43 (87.25%)
Price US$0.93

AEON Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Medium-low risk with weak fundamentals.

7 Risks
0 Rewards

AEON Biopharma, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$39.2m

Other Expenses

-US$39.2m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-1.55
0%
0%
-62.9%
View Full Analysis

About AEON

Founded
n/a
Employees
8
CEO
Robert Bancroft
WebsiteView website
www.aeonbiopharma.com

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.

Recent AEON News & Updates

Recent updates

No updates